A randomized phase II study of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG‑BR 15-10, NCT02592746) - Park, Y H; Kim, T Y; Kim, G M (J Clin Oncol, 2019)
et al.